Same starting point, different paths
Both compounds are synthetic versions of alpha-melanocyte-stimulating hormone, the body's signal for producing pigment. Melanotan I was later developed as afamelanotide. Melanotan II is a smaller ring-shaped molecule that acts on more melanocortin receptors, including ones involved in appetite and sexual function, which helps explain its broader side effects.
Melanotan I: tested and approved for one rare disease
Afamelanotide was tested in randomized trials in erythropoietic protoporphyria (EPP), a rare condition in which sunlight causes severe pain. In two trials published in 2015, people given afamelanotide implants could spend longer in sunlight without pain, and quality-of-life measures improved.
It is approved in the U.S. as Scenesse, an implant placed by trained clinicians for adults with EPP. Its label includes skin-surveillance and pigment-change precautions. The approval covers that implant for that disease, not tanning or research vials.
Source: Afamelanotide for Erythropoietic Protoporphyria. ↗
Source: dailymed.nlm.nih.gov ↗
Melanotan II: a tiny pilot and a safety warning
The first human study of Melanotan II was a 1996 pilot phase 1 trial with three participants. Pigmentation increased in some of them, and nausea, drowsiness and prolonged unwanted erections were reported. Two small trials in 1998 and 2000 later tested it for erectile dysfunction in 20 men; it was never developed further.
FDA's page on compounding substances that may present significant safety risks notes serious adverse-event reports for Melanotan II, including melanoma, a brain-swelling syndrome and priapism. Its compounding nomination was withdrawn, and it is on the agenda for FDA's compounding advisory committee before the end of February 2027. It is not approved for any use. PepsRadar does not list Melanotan II products or link to sellers for it.
Source: doi.org ↗
Source: fda.gov ↗
Source: fda.gov ↗
Where bremelanotide (PT-141) fits
Bremelanotide, also called PT-141, is a related melanocortin drug developed from the same line of research. It is approved in the U.S. as Vyleesi for a specific sexual-desire disorder in premenopausal women, based on two randomized trials. It is a separate medicine with its own label, not a form of Melanotan II.
Source: medlineplus.gov ↗
Continue with the original research
Study examples are based on selected publication abstracts and the explicitly described source documents. This is not a systematic review or an individualized treatment guide. Editorial scope and methods.
